CBS 2019
CBSMD教育中心
中 文

双重抗血小板治疗持续时间

Abstract

Recommended Article

Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial Cost-Effectiveness of Different Durations of Dual-Antiplatelet Use After Percutaneous Coronary Intervention DAPT, Our Genome and Clopidogrel Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel) Adjunctive Cilostazol to Dual Antiplatelet Therapy to Enhance Mobilization of Endothelial Progenitor Cell in Patients with Acute Myocardial Infarction: A Randomized, Placebo-Controlled EPISODE Trial Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial

Editorial01 July 2020

JOURNAL:Eur Heart J. Article Link

Identifying coronary artery disease patients at risk for sudden and/or arrhythmic death: remaining limitations of the electrocardiogram

B Asatryan, L Roten, T Reichlin et al. Keywords: sudden death; arrhythmic death; electrocardiogram; CHD

ABSTRACT

The important study concerning the easy-to-use electrocardiogram (ECG) markers of sudden and/or arrhythmic death (SAD) in coronary artery disease (CAD) patients as presented by Chatterjee et al.1 is a weighty contribution to an intricate and still rather puzzling topic. They implicate that in CAD patients, contiguous Q waves, left ventricular hypertrophy (LVH), QRS duration, and JTc prolongation provide incremental predictive value beyond traditional risk factors for SAD. While this study is unique in providing easily measurable markers that improve SAD risk stratification, it also...